News

Oragenics, Inc. Announces Partnership with BRAINBox Solutions to Revolutionize Concussion Diagnosis and Treatment

Oragenics, Inc. (NYSE American: OGEN), a biotechnology company advancing innovative treatments for concussion and brain-related health conditions,  announced a strategic partnership with BRAINBox Solutions, a leader in multi-modality diagnostics for traumatic brain injury (TBI). This collaboration seeks to develop the first intranasal therapy for mild traumatic brain injury (mTBI) aka concussion, creating a comprehensive trigger-to-treat platform by combining BRAINBox’s advanced multimarker/ multimodality diagnostic capabilities with Oragenics’ novel therapeutic development.

The partnership intends to integrate BRAINBox’s proprietary diagnostic product platform—which utilizes a combination of neurological biomarkers, neuropsychological assessments, and AI-driven analytics to provide early and accurate TBI assessments—with Oragenics’ intranasal therapeutic candidate, ONP-002. ONP-002 is designed to mitigate the effects of brain injury and promote recovery. Together, these technologies aim to transform the standard of care for concussion patients by providing rapid diagnosis, predictive prognosis, and timely, targeted treatment.

“This collaboration represents a significant step forward in concussion care,” said Janet Huffman, Interim Chief Executive Officer of Oragenics. “By combining our innovative intranasal therapeutic with BRAINBox’s state-of-the-art diagnostic product platform, we hope to offer a comprehensive solution that addresses both the identification and treatment of mTBI, ultimately improving patient outcomes. We believe BRAINBox’s diagnostic tools will be instrumental in our upcoming Phase IIa trials, enabling precise patient selection and real-time monitoring of therapeutic efficacy.”

BRAINBox’s testing platform offers both diagnostic and prognostic insights, identifying patients at higher risk for long-term symptoms and guiding personalized treatment strategies. Oragenics’ ONP-002, an intranasal neurosteroid therapeutic, has demonstrated significant potential in preclinical studies to reduce brain injury effects and support recovery. A Phase I clinical trial showed ONP-002 to be well-tolerated and Oragenics’ novel intranasal device to be easily operated. The integration of these technologies could lead to a seamless trigger-to-treat ecosystem, facilitating early intervention and improving outcomes for millions affected by TBI annually.

Donna Edmonds, Chief Executive Officer of BRAINBox Solutions, added, “Partnering with Oragenics allows us to enhance the impact of our diagnostic technology by linking it directly to a promising therapeutic option. Together, we aim to set a new standard in the management of  brain injuries, providing clinicians with the tools they need to deliver timely and effective care.”

With over 5 million concussions occurring annually in the U.S. alone, there is a significant unmet need for effective diagnostic and therapeutic solutions. This partnership positions Oragenics and BRAINBox at the forefront of innovation in TBI care, offering a compelling opportunity for advancing healthcare solutions in neurology.

Learn more here.

Recent News

06/02/2025

Virginia Tech researchers find promise in a new peptide drug to combat a deadly brain cancer

A lab-designed molecule developed and extensively studied by scientists with Virginia Tech’s Fralin Biomedical Research Institute at VTC could represent a breakthrough in slowing tumor recurrence in glioblastoma, an aggressive and deadly form of brain cancer. In a study published May 16 in Cell Death and Disease, researchers identified a previously unknown trait of cancer cells that

05/28/2025

Brandy Salmon named Virginia Tech’s first vice president for innovation and partnerships

Brandy Salmon, who since 2017 has led Virginia Tech teams focused on connecting the university with corporations, foundations, and alumni worldwide has been named the university’s first vice president for innovation and partnerships. “True collaboration between higher education, government, and industry is essential for success in today’s evolving landscape,” said Virginia Tech President Tim Sands.

05/28/2025

Avera Joins Civica to Help Minimize Risk of Drug Shortages

Civica, a nonprofit pharmaceutical company created to prevent and mitigate drug shortages, announced today that Avera, a leading nonprofit healthcare provider in the Upper Midwest United States, has joined the company in helping protect patients from the impact of drug shortages of essential generic sterile injectable medicines. Drug shortages are a persistent challenge to the